Will counselling using an adaptation of motivational interviewing method improve the acceptance of surgery and adherence to treatment and follow up in among glaucoma patients in Bauchi

Randomised controlled trial of adapted motivational interviewing for acceptance and adherence to treatment in glaucoma patients in Bauchi

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN79330571

Enrollment

300

Registered

2013-01-30

Start date

2013-09-01

Completion date

Unknown

Last updated

2019-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma Eye Diseases Glaucoma

Interventions

Current interventions as of 16/09/2013: The intervention is one to two sessions of adapted motivational interview to patients allocated at random. Patients allocated will be interviewe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Primary open angle glaucoma in at least one eye, where surgery or LASER is the treatment of choice in one or both eyes 2. Aged 17 years or more (can give consent) 3. Residence within 200km of Bauchi, the study site 4. Understands and speaks Hausa or English 5. Informed consent

Exclusion criteria

Exclusion criteria: 1. Other forms of treatment other than surgery or LASER more appropriate 2. Other ocular pathology except cataract. 3. Systemic diseases/problems that contraindicate surgery

Design outcomes

Primary

Measure	Time frame
Current primary outcome measures as of 16/09/2013: Proportion of participants who attend for and/or undergo surgery in the study eye, within 2 months of being listed for glaucoma surgery Previous primary outcome measures: Proportion of participants who attend for and/or undergo surgery in the study eye, within 4 months of being listed for glaucoma surgery	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 16/09/2013: 1. Accept surgery within 2 months: 1.1. Proportion of participants who report for follow up at 1, 6 and 12 months following surgery 1.2. Proportion of participants whose IOP is controlled at 1, 6 and 12 months (<20 mmHg in the study eye) 2. Refuse surgery after 2 months: 2.1. Proportion of participants who adhere to medical treatments at each follow up 2.2. Proportion of participants whose IOP is controlled at 1, 6 and 12 months (<20 mmHg in the study eye) Previous secondary outcome measures: 1. Accept surgery within 4 months: 1.1. Proportion of participants who report for follow up at 1, 2, 4 and 6 months following surgery 1.2. Proportion of participants whose IOP is controlled at 1, 2, 4 and 6 months (<20 mmHg in the study eye) 2. Refuse surgery after 4 months: 2.1. Proportion of participants who adhere to medical treatments at each follow up 2.2. Proportion of participants whose IOP is controlled at 1, 2, 4 and 6 months (<20 mmHg in the study eye)	—

Measure

Time frame

Current secondary outcome measures as of 16/09/2013: 1. Accept surgery within 2 months: 1.1. Proportion of participants who report for follow up at 1, 6 and 12 months following surgery 1.2. Proportion of participants whose IOP is controlled at 1, 6 and 12 months (<20 mmHg in the study eye) 2. Refuse surgery after 2 months: 2.1. Proportion of participants who adhere to medical treatments at each follow up 2.2. Proportion of participants whose IOP is controlled at 1, 6 and 12 months (<20 mmHg in the study eye) Previous secondary outcome measures: 1. Accept surgery within 4 months: 1.1. Proportion of participants who report for follow up at 1, 2, 4 and 6 months following surgery 1.2. Proportion of participants whose IOP is controlled at 1, 2, 4 and 6 months (<20 mmHg in the study eye) 2. Refuse surgery after 4 months: 2.1. Proportion of participants who adhere to medical treatments at each follow up 2.2. Proportion of participants whose IOP is controlled at 1, 2, 4 and 6 months (<20 mmHg in the study eye)

—

Countries

Nigeria

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 20, 2026